|
Unit：
|
Taiwan Affairs Office of Fuzhou Municipal People’s Government
|
|
|
Project Area：
|
Fuzhou Cross-Strait Biotech Health Care Demonstration Zone
|
|
|
Industry：
|
Biological and New Pharmaceutical Industry
|
|
|
Type of Project:
|
New Project
|
|
|
Cooperation Mode：
|
Collaborate
|
|
|
Nature of Project：
|
Encourage
|
|
|
Working Progress in Prior Period：
|
none
|
|
|
Total Investment：
|
discussed in detai
|
|
|
Expected to Attract Investment：
|
discussed in detai
|
|
|
Benefit Analysis:
|
none
|
|
|
Reason and Condition：
|
none
|
|
|
Content and Scale：
|
It intends to introduce a group of top 100 competitive enterprises in Taiwan and high-end industrial talents, to fully leverage the market demand and technological advantages of medical services in both Fujian and Taiwan. The project focuses on developing medical services including smart medical care, precision medicine, and regenerative medicine treatment, health care services including elderly and health management, and standardized care, and innovative, application-led, and complementary cell gene therapy and new demonstration bases, and achieve the goal of "aging well and slowly".
|
|
|
Others：
|
none
|
|
In 2025, Fujian Province had 341 above-designated-size pharmaceutical enterprises, achieving an operating revenue of RMB 50.28 billion. The province's pharmaceutical industry has cultivated a relatively comprehensive industrial system covering categories such as chemical APIs (active pharmaceutical ingredients), chemical drug preparations, biopharmaceuticals, traditional Chinese medicine (TCM) prepared prescriptions, TCM decoction pieces, and medical devices. During the "14th Five-Year Plan" period, 4 Category-1 innovative drugs and 4 Category-2 innovative drugs were approved, accelerating industrial innovation. Maxim Biotech and Double Medical were promoted as leaders in the industrial chain. 6 projects from 3 enterprises, including Double Medical, were shortlisted for the Ministry of Industry and Information Technology's List of “Open Bidding for Selecting the Best Candidates for Innovation Tasks in Biomedical Materials.” 11 provincial-level industrial leading enterprises in biomedicine, such as Zhangzhou Pien Tze Huang Pharmaceuticals, and 17 enterprises under cultivation for leading status were fostered. 3 enterprises, including AmoyDx, were recognized as national single-item champions (in specific products); 25 enterprises, including Fukang Pharmaceuticals, were recognized as provincial single-item champions (in specific products). 19 pharmaceutical enterprises, including Southern Pharmaceuticals and Fukang Pharmaceuticals, were recognized as National "Little Giants" Enterprises Using Specialized and Advanced Technologies to Create Innovative and Unique Products. 15 enterprises, including Double Medical, Cosunter Pharmaceutical, and Haixi Pharmaceuticals, are listed companies.
- Marine Biomedical Products Project, Marine Life High-tech Industrial Base
- Biomedicine Project, Pingtan Cross-Strait Medical and Health Industrial Park, Haixi (West Coast) Entry-Exit Animal-Plant Quarantine Center, Drug Safety Evaluation Center (Laboratory Animal Center)
- Biology and New Medicine Project, Zherong High-tech Industrial Park
- Medical Devices Project, Minxi (Changting) Medical Device Industrial Park
- New Medicine and Comprehensive Health Services Project, New Medicine and Health Industry Park, Longyan High-tech Industrial Development Zone
- Biology and New Medicine Project, Putan Industrial Park
Invest Fujian is a professional website to provide Invest Fujian policy, guide and service for foreign investor.
-
Address：
No. 118 Tongpan Road，Gulou District，Fuzhou，China
-
Tel：
-
Fax：
+86-591-83839780
-
Email：
tczx4@swt.fujian.gov.cn
- Sponsor： Fujian Provincial Department of Commerce
- Organizer： Fujian Investment Promotion Center
- Copyright： Invest Fujian,China 闽ICP备14009608号-12
